<DOC>
	<DOCNO>NCT02507258</DOCNO>
	<brief_summary>MicroPort Orthopedics ( MPO ) conduct post market clinical follow-up ( PMCF ) study evaluate safety efficacy total hip arthroplasty ( THA ) resurface component market European Union ( EU ) . These type study require regulatory authority THA resurface device medium long-term clinical evidence available time gain approval market EU . This study design accordance medial device directive ( MEDDEV ) 2.12/2 rev 2 .</brief_summary>
	<brief_title>PMCF Study PROFEMUR® Am Femoral Components PROCOTYL® O HA Coated Acetabular Components</brief_title>
	<detailed_description />
	<mesh_term>Joint Diseases</mesh_term>
	<criteria>Subject undergone primary THA following : Noninflammatory degenerative joint disease osteoarthritis , avascular necrosis , ankylosis , protrusio acetabuli , painful hip dysplasia ; Inflammatory degenerative joint disease rheumatoid arthritis ; Correction functional deformity Subject implant specified combination component Subject willing able complete require study visit assessment Subjects skeletally immature ( less 21 year age ) time primary THA surgery Subjects implant nonMPO component ( femoral stem , femoral head , acetabular liner ) enrol THA Subjects currently enrol another clinical study could affect endpoint protocol Subjects unwilling sign Informed Consent document Subjects substance abuse issue Subjects incarcerate pending incarceration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>